Investors sold shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on strength during trading hours on Wednesday following insider selling activity. $60.88 million flowed into the stock on the tick-up and $95.66 million flowed out of the stock on the tick-down, for a money net flow of $34.78 million out of the stock. Of all companies tracked, Regeneron Pharmaceuticals had the 22nd highest net out-flow for the day. Regeneron Pharmaceuticals traded up $0.42 for the day and closed at $456.05Specifically, SVP Robert E. Landry sold 526 shares of the firm’s stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $472.19, for a total transaction of $248,371.94. Following the completion of the transaction, the senior vice president now directly owns 9,099 shares in the company, valued at $4,296,456.81. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Charles A. Baker sold 2,000 shares of the firm’s stock in a transaction on Friday, September 29th. The stock was sold at an average price of $450.00, for a total value of $900,000.00. Following the transaction, the director now owns 11,000 shares of the company’s stock, valued at $4,950,000. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 87,968 shares of company stock valued at $41,599,948. Company insiders own 10.80% of the company’s stock.
A number of research analysts recently issued reports on the company. J P Morgan Chase & Co reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, August 15th. Leerink Swann reiterated an “outperform” rating and issued a $580.00 target price (up from $573.00) on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 9th. Zacks Investment Research upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $540.00 target price for the company in a report on Wednesday, August 9th. Robert W. Baird lowered Regeneron Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $408.00 target price for the company. in a report on Tuesday, August 8th. Finally, Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and issued a $472.00 target price (up from $469.00) on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 9th. Two analysts have rated the stock with a sell rating, fifteen have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $487.26.
The firm’s 50 day moving average price is $460.77 and its 200 day moving average price is $451.15. The firm has a market cap of $48.36 billion, a P/E ratio of 45.75 and a beta of 1.62.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, beating the consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The company had revenue of $1.47 billion for the quarter, compared to analyst estimates of $1.36 billion. During the same quarter last year, the business earned $2.82 earnings per share. Regeneron Pharmaceuticals’s revenue was up 21.2% compared to the same quarter last year. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post $14.93 earnings per share for the current fiscal year.
Large investors have recently made changes to their positions in the business. Fieldpoint Private Securities LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $130,000. Sterling Investment Advisors Ltd. increased its stake in shares of Regeneron Pharmaceuticals by 11.2% in the second quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock valued at $137,000 after purchasing an additional 28 shares during the period. FNY Managed Accounts LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at approximately $140,000. FNY Partners Fund LP boosted its holdings in shares of Regeneron Pharmaceuticals by 200.0% in the second quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock valued at $147,000 after acquiring an additional 200 shares in the last quarter. Finally, Alpha Windward LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 0.3% in the second quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock valued at $189,000 after acquiring an additional 1 shares in the last quarter. Institutional investors own 67.95% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Traders Sell Regeneron Pharmaceuticals, Inc. (REGN) on Strength Following Insider Selling” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2017/10/04/traders-sell-regeneron-pharmaceuticals-inc-regn-on-strength-following-insider-selling.html.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.